138 results
Page 3 of 7
8-K
EX-99.1
h5vfa4s
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
ziyu9mc6z0u2cdka4cxn
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
2h2bq0
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
5zxokrdpt93
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
PRE 14A
p390j00 3yl6f2d
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
92aodqfekl210fu hun
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
gvvbushmbhed036
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-99.1
vzt14pc 76cpk
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
EX-1.1
pzp8u
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
8-K
EX-99.1
hd0703gzmjmh9q3up
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
6x4dr ab43a4uf5f883c
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am